Role of recombinant human growth hormone in HIV-associated wasting and cachexia: Pathophysiology and rationale for treatment

Clinical Therapeutics

Volumn 29, Issue 11, 2007, Pages 2269-2288

  Gelato, Marie ^a   McNurlan, Margaret ^b   Freedland, Eric ^c  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c EMD SERONO INC   (United States)

Author keywords

cachexia; growth hormone; HIV

Indexed keywords

DIDANOSINE; HUMAN GROWTH HORMONE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; LAMIVUDINE; MYOSTATIN; NANDROLONE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; ZALCITABINE;

ARTHRALGIA; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CACHEXIA; CD4 LYMPHOCYTE COUNT; CELL DISRUPTION; CLINICAL FEATURE; CLINICAL STUDY; CYTOKINE RESPONSIVE ELEMENT; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFECT; ENDURANCE; ENERGY EXPENDITURE; FAT BODY; FEVER; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GONAD DYSFUNCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPESTHESIA; INCIDENCE; INFLAMMATION; LEAN BODY WEIGHT; METABOLIC DISORDER; MULTIVARIATE ANALYSIS; MYALGIA; MYOPATHY; NUTRITIONAL DEFICIENCY; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PROTEIN DEGRADATION; PROTEIN METABOLISM; QUALITY OF LIFE; RESTING ENERGY EXPENDITURE; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; THRUSH; TREATMENT INDICATION; VIROLOGY; VIRUS LOAD; WASTING SYNDROME;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; CACHEXIA; CHILD; CYTOKINES; ENERGY METABOLISM; GROWTH HORMONE; HIV INFECTIONS; HIV WASTING SYNDROME; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MUSCULAR DISEASES; PROTEINS; RECOMBINANT PROTEINS; RISK FACTORS; SIGNAL TRANSDUCTION; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA;

EID: 37349034238     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.11.004     Document Type: Article

References (90)

1. Grinspoon S., Mulligan K., and for the Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and Weight Loss. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis 36 Suppl 2 (2003) S69-S78
2. Centers for Disease Control (CDC). Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep 36 Suppl 1 (1987) 1S-15S
3. Mangili A., Murman D., Zampini A., and Wanke C. Nutrition and HIV infection: Review of weight loss and wasting in the era of highly active antiretroviral therapy from the Nutrition for Healthy Living cohort. Clin Inflect Dis 42 (2006) 836-842
4. Palenicek J., Graham N., He Y., et al., for the Multicenter AIDS Cohort Study Investigators. Weight loss prior to clinical AIDS as a predictor of survival. J Acquir Immune Defic Syndr Hum Retrovirol 10 (1995) 366-373
5. Morley J., Thomas D., and Wilson M. Cachexia: Pathophysiology and clinical relevance. Am J Clin Nutr 83 (2006) 735-743
6. Roubenoff R., Heymsfield S., Kehayias J., et al. Standardization of nomenclature of body composition in weight loss. Amy Clin Nutr 66 (1997) 192-196
7. Kotler D. Cachexia. Ann Intern Med 133 (2000) 622-634
8. Springer J., yon Haehling S., and Anker S. The need for a standardized definition for cachexia in chronic illness. Nat Clin Pract Endocrinol Metab 2 (2006) 416-417
9. Ockenga J., Grimble R., Jonkers-Schuitema C., et al., for the DGEM (German Society for Nutritional Medicine) and the ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN guidelines on enteral nutrition: Wasting in HIV and other chronic infectious diseases. Clin Nutr 25 (2006) 319-329
10. Polo R., Gomez-Candela C., Miralles C., et al., for SPNS/GEAM/SENBA/SENPE/AEDN/SEDCA/GESIDA. Recommendations from SPNS/GEAM/SENBA/SENPE/AEDN/SEDCA/GESIDA on nutrition in the HIV-infected patient. Nutr Hosp 22 (2007) 229-243
11. American Gastroenterological Association medical position statement. Guidelines for the management of malnutrition and cachexia, chronic diarrhea, and hepatobiliary disease in patients with human immunodeficiency virus infection. Gastroenterology 111 (1996) 1722-1723
12. Grinspoon S., Corcoran C., Rosenthal D., et al. Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome. J Clin Endocrinol Metab 84 (1999) 201-206
13. Wilson I., and Cleary P. Clinical predictors of declines in physical Functioning in persons with AIDS: Results of a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 16 (1997) 343-349
14. Dworkin M., Williamson J., and for the Adult/Adolescent Spectrum of HIV Disease Project. AIDS wasting syndrome: Trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr 33 (2003) 267-273
15. Wheeler D., Gibert C., Launer C., et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 18 (1998) 80-85
16. Chaisson R., Gallant J., Keruly J., and Moore R. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 12 (1998) 29-33
17. Chlebowski R., Grosvenor M., Bernhard N., et al. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 84 (1989) 1288-1293
18. Guenter P., Muurahainen N., Simons G., et al. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr 6 (1993) 1130-1138
19. Tang A., Jacobson D., Spiegelman D., et al. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr 40 (2005) 70-76
20. Thiebaut R., Malvy D., Marimoutou C., Davis F., and for the Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Anthropometric indices as predictors of survival in AIDS adults. Aquitaine Cohort, France, 1985-1997. Eur J Epidemiol 16 (2000) 633-639
21. Charurat M., Blattner W., Hershow R., et al., for the Women and Infants Transmission Study. Changing trends in clinical AIDS presentations and survival among HIV-1-infected women. J Womens Health (Larchmt) 13 (2004) 719-730
22. Conti S., Masocco M., Pezzotti P., et al. Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J Acquir Immune Defic Syndr 25 (2000) 451-458
23. Moore R., and Chaisson R. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 13 (1999) 1933-1942
24. McDermott A., Shevitz A., Knox T., et al. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 74 (2001) 679-686
25. Dolan S., Montagno A., Wilkie S., et al. Neurocognitive function in HIV-infected patients with low weight and weight loss. J Acquir Immune Defic Syndr 34 (2003) 155-164
26. McNaughten A., Hanson D., and Sullivan P. Changing influence of antiretroviral therapy (ART) on opportunistic illnesses (OIs) in the US, 1994-2003. Presented at: Third International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27, Rio de Janiero, Brazil (2005)
27. Maia B., Engelson E., Wang J., and Kotler D. Antiretroviral therapy affects the composition of weight loss in HIV infection: Implications for clinical nutrition. Clin Nutr 24 (2005) 971-978
28. Grinspoon S., Corcoran C., Miller K., et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. [published correction appears in J Clin Endocrinol Metab. 1997;82:3360]. J Clin Endocrinol Metab 82 (1997) 1332-1337
29. Mulligan K., Tai V., and Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 15 (1997) 43-48
30. Furrer H., Chan P., Weber R., Egger M., and for the Swiss HIV Cohort Study. Increased risk of wasting syndrome in HIV-infected travellers: Prospective mu Iticentre study. Trans R Soc Trop Med Hyg 95 (2001) 484-486
31. Lyles R., Tang A., Smit E., et al. Virologic, immunologic, and immune activation markers as predictors of HIV-associated weight loss prior to AIDS Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 22 (1999) 386-394
32. Zackin I., Clark I., Currier J., and Mildvan D. Predictive markers of HIV-related weight loss and determination of differences between populations with weight loss stratified by opportunistic processes. J Acquir Immune Defic Syndr 22 (1999) 189-193
33. Zingmond D., Kilbourne A., Justice A., et al. Differences in symptom expression in older HIV-positive patients: The Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr 33 Suppl 2 (2003) S84-S92
34. Roubenoff R., Grinspoon S., Skolnik P., et al. Role ofcytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. Am J Physiol Endocrinol Metab 283 (2002) E138-E145
35. Elenkov I., lezzoni D., Daly A., et al. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 12 (2005) 255-269
36. Guttridge D., Mayo M., Madrid L., et al. NF-kappaB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science 289 (2000) 2363-2366
37. Di Marco S., Mazroui R., Dallaire P., et al. NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol Cell Biol 25 (2005) 6533-6545
38. Acharyya S., Ladner K., Nelsen L., et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114 (2004) 370-378
39. Jackman R., and Kandarian S. The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 287 (2004) C834-C843
40. Feingold K., Marshall M., Gulli R., et al. Effect ofendotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb 14 (1994) 1866-1872
41. Liao W., and Floren C. Upregulation of low density lipoprotein receptor activity by tumor necrosis factor, a process independent of tumor necrosis factor-induced lipid synthesis and secretion. Lipids 29 (1994) 679-684
42. Constans J., Pellegrin I., Pellegrin J., et al. Plasma interferon alpha and the wasting syndrome in patients infected with the human immunodeficiency virus. Clin Infect Dis 20 (1995) 1069-1070
43. Rimaniol A., Zylberberg H., Zavala F., and Viard J. Inflammatory cytokines and inhibitors in HIV infection: Correlation between interleukin-1 receptor antagonist and weight loss. AIDS 10 (1996) 1349-1356
44. Suttmann U., Selberg O., Gallati H., et al. Tumour necrosis factor receptor levels are linked to the acutephase response and malnutrition in h u man-im mu nodeficiency-virus infected patients. Clin Sci (Lond) 86 (1994) 461-467
45. Melchior J., Salmon D., Rigaud D., et al. Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 53 (1991) 437-441
46. Mulligan K., and Schambelan M. HIV-associated wasting [HIV InSite Web site] (2003), University of California San Francisco and San Francisco General Hospital, San Francisco, Calif. http://hivinsite.ucsf.edu/InSite?page=kb-04doc=kb-04-01-08 Accessed September 19, 2007
47. Macallan D., Noble C., Baldwin C., et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 333 (1995) 83-88
48. Shevitz A., Knox T., Spiegelman D., et al. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 13 (1999) 1351-1357
49. Grunfeld C., and Feingold K. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 327 (1992) 329-337
50. Schurmeyer T., Muller V., von zur Muhlen A., and Schmidt R. Endocrine testicular function in HIV-infected outpatients. Eur J Med Res 2 (1997) 275-281
51. Coodley G., Loveless M., Nelson H., and Coodley M. Endocrine function in the HIV wasting syndrome. J Acquir Immune Defic Syndr 7 (1994) 46-51
52. Dobs A., Few III W., Blackman M., et al. Serum hormones in men with human immunodeficiency virus associated wasting. J Clin Endocrinol Metab 81 (1996) 4108-4112
53. Grinspoon S., Corcoran C., Lee K., et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 81 (1996) 4051-4058
54. Gonzalez-Cadavid N., Taylor W., Yarasheski K., et al. Organization of the human myostatin gene and expression in healthy men and HIV- infected men with muscle wasting. Proc Natl Acad Sci USA 95 (1998) 14938-14943
55. Liu W., Thomas S., Asa S., et al. Myostatin is a skeletal muscle target of growth hormone anabolic action. J Clin Endocrinol Metab 88 (2003) 5490-5496
56. Miro O., Pedrol E., Cebrian M., et al. Skeletal muscle studies in patients with HIV-related wasting syndrome. J Neurol Sci 150 (1997) 153-159
57. Yarasheski K., Smith S., and Powderly W. Reducing plasma HIV RNA improves muscle amino acid metabolism. Am J Physiol Endocrinol Metab 288 (2005) E278-E284
58. Yarasheski K., Zachwieja J., Gischler J., et al. Increased plasma gin and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol 275 (1998) E577-E583
59. Rivera S., Briggs W., Qian D., and Sattler F. Levels of H IV RNA are quantitatively related to prior weight loss in HIV-associated wasting. J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998) 411-418
60. McDermott A., Terrin N., Wanke C., et al. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: A longitudinal study. Clin Infect Dis 41 (2005) 1662-1670
61. Justice A., Stein D., Fusco G., et al. Disease progression in HIV-infected patients treated with stavudine vs zidovudine. J Clin Epidemiol 57 (2004) 89-97
62. Kotler D., Tierney A., Wang J., and Pierson Jr. R. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 50 (1989) 444-447
63. Kotler D., Wang J., and Pierson R. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 42 (1985) 1255-1265
64. Grunfeld C. What causes wasting in AIDS?. N Engl J Med 333 (1995) 123-124
65. Lavie CJ, Mehra MR, Milani RV. Obesity and heart failure prognosis: Paradox or reverse epidemiology?
66. Lieberman S., Butterfield G., Harrison D., and Hoffman A. Anabolic effects of recombinant insulin-like growth factor-1 in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 78 (1994) 404-410
67. Mitch W., and Goldberg A. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 335 (1996) 1897-1905
68. Grinspoon S., Corcoran C., Stanley T., et al. Effects of androgen administration on the growth hormoneinsulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 83 (1998) 4251-4256
69. Schurgin S., Dolan S., Perlstein A., et al. Effects of testosterone administration on growth hormone pulse dynamics in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 89 (2004) 3290-3297
70. Krentz A., Koster F., Crist D., et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 6 (1993) 245-251
71. Mulligan K., Grunfeld C., Hellerstein M., et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiencyvirus infection. J Clin Endocrinol Metab 77 (1993) 956-962
72. Moyle G., Daar E., Gertner J., et al., for the Serono 9037 Study Team. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 35 (2004) 367-375
73. Mulligan K., Tai V., and Schambelan M. Effects of chronic growth hormone treatment on energy intake and resting energy metabolism in patients with human immunodeficiencyvirusassociated wasting-a clinical research center study. J Clin Endocrinol Metab 83 (1998) 1542-1547
74. Schambelan M., Mulligan K., Grunfeld C., et al., for the Serostim Study Group. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Ann Intern Med 125 (1996) 873-882
75. Hardin D., Rice J., Doyle M., and Pavia A. Growth hormone improves protein catabolism and growth in prepubertal children with HIV infection. Clin Endocrinol (Oxf) 63 (2005) 259-262
76. Hardin D., Ellis K., Rice J., and Doyle M. Protease inhibitor therapy improves protein catabolism in prepubertal children with HIV infection. J Pediatr Endocrinol Metab 17 (2004) 321-325
77. Esposito J., Thomas S., Kingdon L., and Ezzat S. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: A randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 5124-5131
78. Evans W., Kotler D., Staszewski S., et al. Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. AIDS Read 15 (2005) 301-314
79. Storer T., Woodhouse L., Sattler F., et al. A randomized, placebocontrolled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 90 (2005) 4474-4482
80. Waters D., Danska J., Hardy K., et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS- associated wasting. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 125 (1996) 865-872
81. Jeffcoate W. Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: A review of recent evidence. Drug Saf 25 (2002) 199-212
82. Laurence J., Grimison B., and Gonenne A. Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro. Blood 79 (1992) 467-472
83. Bustin S., and Jenkins P. The growth hormone-insulin-like growth factor I axis and colorectal cancer. Trends Mol Med 7 (2001) 447-454
84. Laban C., Bustin S., and Jenkins P. The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 14 (2003) 28-34
85. Critical evaluation of the safety of recombinant human growth hormone administration. Statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 86 (2001) 1868-1870
86. Juul A., Bernasconi S., Carel J., et al. Growth hormone treatment and risk of solid tumours. A statement from the Drugs and Therapeutics Committee of the European Society for Paediatric Endocrinology (ESPE). Horm Res 60 (2003) 103-104
87. Ma J., Pollak M., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer lnst 91 (1999) 620-625
88. Serostim (somatropin [rDNA origin] for injection) [package insert] (2007), EMD Serono Inc, Rockland, Mass
89. Ellis K., Lee P., Pivarnik J., et al. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone. J Clin Endocrinol Metab 81 (1996) 3033-3038
90. Lee P., Pivarnik J., Bukar J., et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. [published correction appears in J Clin Endocrinol Metab. 1996;81:3696]. J Clin Endocrinol Metab 81 (1996) 2968-2975